SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting

- Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools - - Substantial Reductions in MRI-Assessed Tumor Volume... | May 25, 2023

Related Keywords

Denmark ,United States ,France ,Coindre ,Auvergne ,American ,Samantha Hilson Sandler ,Jim Cassidy ,Fred Hutchinson Cancer Research Center ,European Organization For Research ,Twitter ,European Consensus Initiative ,Desmoid Tumor Working Group ,Desmoid Working Group ,American Society Of Clinical Oncology ,European Society For Medical Oncology Congress ,Springworks Therapeutics Inc ,Linkedin ,Nasdaq ,Bone Sarcoma Group ,European Commission ,Drug Administration ,Dana Farber Cancer Institute ,Treatment Demonstrated Rapid ,Consistent Reductions ,Spain Compared ,Placebo Using Multiple Assessment Tools ,Assessed Tumor Volume ,Nirogacestat Compared ,Works Therapeutics ,Clinical Oncology ,Annual Meeting ,European Society ,Medical Oncology Congress ,New England Journal ,Chief Medical Officer ,New Drug Application ,Session Date ,Poster Discussion ,Defi Trial ,Response Evaluation Criteria ,Solid Tumors ,Time Oncology Review ,Priority Review ,Prescription Drug User Fee Act ,Fast Track ,Breakthrough Therapy Designations ,Orphan Drug Designation ,Private Securities Litigation Reform Act ,Springwork Quarterly Report ,Investor Relations ,Hilson Sandler ,Gamma Secretase Inhibitor ,Desmoid Working ,European Organization ,Soft Tissue ,Mayo Clinic ,Desmoid Tumors ,Report Series ,Rare Diseases ,Desmoid Tumor Working ,Springworks Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Nirogacestat ,Treatment ,Remonstrated ,Sustained ,End ,Consistent ,Reductions ,N ,Rain ,Ompared ,O ,Placebo ,Sing ,Multiple ,Assessment ,Tools ,Ubstantial ,Umor Swtx Us85205l1070 ,